Some of these data were confirmed using HER2-CAR T cells, including showing the greatest tumor cell killing, highest CD137 activation, and enhanced antigen-dependent T-cell proliferation when CD28tm was coupled with the 4-1BB costimulatory domain (Fig. S4e–h). This evidence concerns the gene TNFRSF9 and neoplasm.